These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 28754388)

  • 1. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.
    Bosch J; Eikelboom JW; Connolly SJ; Bruns NC; Lanius V; Yuan F; Misselwitz F; Chen E; Diaz R; Alings M; Lonn EM; Widimsky P; Hori M; Avezum A; Piegas LS; Bhatt DL; Branch KRH; Probstfield JL; Liang Y; Liu L; Zhu J; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Fox KAA; Kakkar A; Parkhomenko AN; Ertl G; Störk S; Keltai K; Keltai M; Ryden L; Dagenais GR; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim JH; Ha JW; Tonkin AM; Varigos JD; Lewis BS; Felix C; Yusoff K; Steg PG; Aboyans V; Metsarinne KP; Anand SS; Hart RG; Lamy A; Moayyedi P; Leong DP; Sharma M; Yusuf S
    Can J Cardiol; 2017 Aug; 33(8):1027-1035. PubMed ID: 28754388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Cook Bruns N; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar A; Parkhomenko AN; Ryden L; Pogosova N; Dans A; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik T; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne K; Fox KAA; Yusuf S;
    Gastroenterology; 2019 Aug; 157(2):403-412.e5. PubMed ID: 31054846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
    Tsilimigras DI; Moris D; Karaolanis G; Kakkos SK; Filis K; Sigala F
    Curr Pharm Des; 2018; 24(38):4516-4517. PubMed ID: 30621559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
    Bhagirath VC; Eikelboom JW; Anand SS
    Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
    Lamy A; Eikelboom J; Sheth T; Connolly S; Bosch J; Fox KAA; Zhu J; Lonn E; Dagenais G; Widimsky P; Branch KRH; Bhatt DL; Zheng Z; Straka Z; Dagenais F; Kong Y; Marsden T; Lee SF; Copland I; Yusuf S
    J Am Coll Cardiol; 2019 Jan; 73(2):121-130. PubMed ID: 30654882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
    J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
    Zhu H; Xu X; Fang X; Ying F; Song L; Gao B; Tong G; Zhou L; Chen T; Huang J
    J Am Heart Assoc; 2021 Mar; 10(6):e019184. PubMed ID: 33682435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial.
    Gaba P; Bhatt DL; Dagenais GR; Bosch J; Maggioni AP; Widimsky P; Leong D; Fox KAA; Yusuf S; Eikelboom JW;
    JAMA Netw Open; 2022 Nov; 5(11):e2243201. PubMed ID: 36409491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD.
    Scott LJ
    Drugs; 2020 Sep; 80(14):1465-1475. PubMed ID: 32910441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
    Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Bruns NC; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar AK; Parkhomenko AN; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne KP; Fox KAA; Yusuf S;
    Gastroenterology; 2019 Sep; 157(3):682-691.e2. PubMed ID: 31152740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
    Eikelboom JW; Bosch J; Connolly SJ; Tyrwitt J; Fox KAA; Muehlhofer E; Neumann C; Tasto C; Bangdiwala SI; Diaz R; Alings M; Dagenais GR; Leong DP; Lonn EM; Avezum A; Piegas LS; Widimsky P; Parkhomenko AN; Bhatt DL; Branch KRH; Probstfield JL; Lopez-Jaramillo P; Rydén L; Pogosova N; Keltai K; Keltai M; Ertl G; Stoerk S; Dans AL; Lanas F; Liang Y; Zhu J; Torp-Pedersen C; Maggioni AP; Commerford PJ; Guzik TJ; Vanassche T; Verhamme P; O'Donnell M; Tonkin AM; Varigos JD; Vinereanu D; Felix C; Kim JH; Ibrahim KS; Lewis BS; Metsarinne KP; Aboyans V; Steg PG; Hori M; Kakkar A; Anand SS; Lamy A; Sharma M; Yusuf S
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 8(8):786-795. PubMed ID: 35383832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
    Guzik TJ; Ramasundarahettige C; Pogosova N; Lopez-Jaramillo P; Dyal L; Berkowitz SD; Muehlhofer E; Bhatt DL; Fox KAA; Yusuf S; Eikelboom JW
    J Am Coll Cardiol; 2021 Feb; 77(5):511-525. PubMed ID: 33538248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
    Kruger PC; Guzik TJ; Eikelboom JW
    Kardiol Pol; 2019 Aug; 77(7-8):661-669. PubMed ID: 31144674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rivaroxaban with aspirin for the secondary prevention of cardiovascular events in Chinese patients with stable cardiovascular diseases: subgroup analysis of COMPASS].
    Liang Y; Gong ZB; Lou KJ; Liu LS; Zhu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Sep; 49(9):873-879. PubMed ID: 34530594
    [No Abstract]   [Full Text] [Related]  

  • 16. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
    Fox KAA; Eikelboom JW; Shestakovska O; Connolly SJ; Metsarinne KP; Yusuf S
    J Am Coll Cardiol; 2019 May; 73(18):2243-2250. PubMed ID: 31072566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
    Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang WJ; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S
    Eur Heart J Qual Care Clin Outcomes; 2023 Aug; 9(5):502-510. PubMed ID: 36001989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke Outcomes in the COMPASS Trial.
    Sharma M; Hart RG; Connolly SJ; Bosch J; Shestakovska O; Ng KKH; Catanese L; Keltai K; Aboyans V; Alings M; Ha JW; Varigos J; Tonkin A; O'Donnell M; Bhatt DL; Fox K; Maggioni A; Berkowitz SD; Bruns NC; Yusuf S; Eikelboom JW
    Circulation; 2019 Feb; 139(9):1134-1145. PubMed ID: 30667279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States.
    Hernandez L; Shah A; Zhao Q; Milentijevic D; Kharat A
    Am Health Drug Benefits; 2020; 13(5):184-190. PubMed ID: 33343818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
    Fox KAA; Anand SS; Aboyans V; Cowie MR; Debus ES; Zeymer U; Monje D; Vogtländer K; Lawatscheck R; Gay A
    Am Heart J; 2020 Apr; 222():166-173. PubMed ID: 32092505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.